Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 4 March 2021, 08:12 HKT/SGT
Share:
    

Source: Eisai
Eisai to Support Construction of Screening Framework for the Novel Coronavirus Infection in Kenya

TOKYO, Mar 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has decided to assent to and support a project led by CA Medlynks Kenya, Ltd., a subsidiary of the healthcare startup company engaged in improving healthcare access in Africa, Connect Afya Co., Ltd., which aims to build a new structure for the efficient testing framework for the novel coronavirus infection in Kenya. CA Medlynks Kenya, Ltd., in collaboration with the government of Meru County in Kenya, will support the setup of PCR testing laboratories, along with procurement of equipment necessary for testing and training of screening technicians.

Meru County, one of Kenya's 47 counties, is the most populous county in the Eastern Province of Kenya with approximately 1.35 million people. As the novel coronavirus infection spreads in Kenya, one issue in Meru County is the time required to receive screening results as samples must be sent across over 200 kilometers to the capital city of Nairobi for testing, a situation which is caused by a lack of equipment, facilities and technicians necessary for screening of the novel coronavirus. It is expected that support for this effort will contribute largely to the formation of accurate and rapid understanding of the infection situation as well as strategy that is based on that understanding by construction of PCR testing in Meru County.

Eisai has committed the equivalent of 1 million USD in aid over the span of 1 year in order to support the controlling of the spread of the novel coronavirus infection in Africa, along with prevention of delays of elimination activities for neglected tropical diseases (NTDs). As part of this support, Eisai has begun provision of Personal Protection Equipment (masks, goggles, face shields, etc.) to core hospitals in Africa for research of and countermeasures against infectious diseases, as well as masks and sanitizer for the resuming of mass drug administrations in Kenya for the elimination of NTDs. In addition, Eisai is supporting Amref Health Africa in the development and popularization of its mobile health platform LEAP for healthcare workers in sub-Saharan countries.

Through this support, including the new support for Connect Afya, Eisai will continue in its contribution to mitigating the spread of the novel coronavirus infection in Kenya and other African countries.

About Connect Afya Co., Ltd. and CA Medlynks Kenya, Ltd.

Connect Afya Co., Ltd. (Headquarters: Hyogo, Japan, CEO: Yoichi Shimada) and its local affiliate CA Medlynks Kenya Ltd. (Location: Nairobi are startups delivering clinical laboratory services and providing in-vitro diagnostic medical equipment, for the realization of a society where people enjoy better lives without suffering from limitations of insufficient medical infrastructure.

As of February 2021, the startup has supplied diagnostic services and in-vitro diagnostic medical equipment, including novel coronavirus infection reverse transcription PCR screening equipment, to over thirty healthcare organizations, clinics, and corporations across Kenya.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: